Drug guidance
Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
Condition
Cancer
8 February 2023
Published on 08 Feb 2023
Last Updated on 08 Feb 2023
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (DBCd) for inclusion on the MOH List of Subsidised Drugs for treating patients with newly diagnosed light chain (AL) amyloidosis in view of the uncertain extent of clinical benefit and uncertain cost-effectiveness compared with the current treatment option.
Clinical indication, subsidy class and MediShield Life claim limit for daratumumab for AL amyloidosis are provided in the Annex.
PES Daratumumab for treating light chain amyloidosis (Published 8 Feb 2023) [PDF, 120 KB]